Check out DDXS. Grandslam. Only PLAC test for Glaxo's inhibitor, darapladib. Glaxo has 2 phase 3 studies lasting 4 years, with results due this month. Billions invested and 27,000 patients enrolled to prove its effectiveness. DDXS has the only test cleared to measure the PLAC levels. Gap up on phase 3 results. Even without darapladib, they have 12 consecutive quarters of revenue growth @20% YoY.